Advertisement

Prognostic and Predictive Factors

  • Laura Biganzoli
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Prognostic factors are key elements for medical oncologists to select, among the group of patients with early breast cancer, those who are candidates for an adjuvant treatment based on their risk of tumor relapse. Predictive factors drive the decision of which type(s) of treatment should be given.

Keywords

Breast Cancer Estrogen Receptor Early Breast Cancer Recurrence Score Adjuvant Tamoxifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Park WB, Kim SI, Kim EK, et al. Impact of patient age on the outcome of primary breast carcinoma. J Surg Oncol. 2002;80:12–8, 2002.PubMedCrossRefGoogle Scholar
  3. 3.
    Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000;355:1869–74.PubMedCrossRefGoogle Scholar
  4. 4.
    El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;6:194 [Epub ahead of print]PubMedCrossRefGoogle Scholar
  5. 5.
    Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17:1497–503.PubMedCrossRefGoogle Scholar
  6. 6.
    Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235:10–26.PubMedCrossRefGoogle Scholar
  7. 7.
    Shetty MR, Reiman HM Jr. Tumor size and axillary metastasis: A correlative occurrence in 1244 cases of breast cancer between 1980 and 1995. Eur J Surg Oncol. 1997;23:139–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–87.PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer. 1993;71(6):2141–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentil nodes in breast cancer. Br J Surg. 2004;91:1245–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Colleoni M, Rotmensz N, Perruzzotti G, et al. Size of breast cancer metastases in axillary lymph nodes: Clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005;23:1379–89.PubMedCrossRefGoogle Scholar
  12. 12.
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991;19:1403–10.CrossRefGoogle Scholar
  13. 13.
    Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. Natl Cancer Inst. 2006;98:262–72.CrossRefGoogle Scholar
  14. 14.
    Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist. 2003;8:307–25, 2003PubMedCrossRefGoogle Scholar
  15. 15.
    Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994;24:41–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Kato T, Kameoka S, Kimura T, et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer. 2003;88:1900–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Hasebe T, Sasaki S, Imoto S, et al. Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: A prospective study. Hum Pathol. 2004;35:298–308.PubMedCrossRefGoogle Scholar
  18. 18.
    Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphvascular invasion in invasive breast cancer. Ann Surg. 2004;240:306–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Davis BW, Gelber RD, Goldhirisch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials for adjuvant therapy for breast cancer. J Clin Oncol. 1999;17:1474.Google Scholar
  20. 20.
    de Mascarel I, Bonichon F, Durand M, et al. Obvious peritumoral emboli: An elusive prognostic factor reappraised. Eur J Cancer. 1998;34:58–65.CrossRefGoogle Scholar
  21. 21.
    Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol. 2007;4:30–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Harbeck N, Kates RE, Schmitt M, et al. Urokinase-type plasminogen activator and ist inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Harbeck N. Pooled analysis validates predictive impact uPA and PAI-1 for response to adjuvant chemotherapy in breast cancer. Breast. 2005;14(l):S27.CrossRefGoogle Scholar
  24. 24.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.PubMedCrossRefGoogle Scholar
  26. 26.
    van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.PubMedCrossRefGoogle Scholar
  27. 27.
    van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.PubMedCrossRefGoogle Scholar
  28. 28.
    Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, et al. Gene expression predictors of breast cancer outcomes. Lancet. 2003;361(9369):1590–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.PubMedCrossRefGoogle Scholar
  31. 31.
    Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702–8.PubMedGoogle Scholar
  33. 33.
    De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res. 2003;9:1039–46.PubMedGoogle Scholar
  34. 34.
    Stal O, Borg A, Ferno M, et al. ErbB2 status and the benefit from 2 or 5 years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol. 2000;11:1545–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Climent MA, Seguì MA, Peirò G, et al. Prognostic value of HER-2/neu and p-53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. The Breast. 2001;10:67–77.PubMedCrossRefGoogle Scholar
  36. 36.
    Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p-53 expression versus tamoxifen resistance in estrogen receptor positive, node-positive breast cancer. J Clin Oncol. 2000;18:3471–9.PubMedGoogle Scholar
  37. 37.
    Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER-2, p-53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol. 2001;19:3376–84.PubMedGoogle Scholar
  38. 38.
    Dowsett M, Allred DC, on behalf of the TransATAC investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat. 2006;100:S21(Abstract 48).Google Scholar
  39. 39.
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16.PubMedGoogle Scholar
  40. 40.
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.PubMedCrossRefGoogle Scholar
  41. 41.
    Elledge RM, Green S, Howes L, et al. bcl-2, p-53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. J Clin Oncol. 1997;15:1916–22.PubMedGoogle Scholar
  42. 42.
    Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1995;1:189–98.Google Scholar
  43. 43.
    Cardoso F, Paesmans M, Larsimont D, et al. Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer. 2004;5:364–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  45. 45.
    Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.PubMedCrossRefGoogle Scholar
  46. 46.
    Allred DC, Clarck GM, Tandon AK, et al. HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol. 1992;10:599–605.PubMedGoogle Scholar
  47. 47.
    Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol. 1992;10:1049–56.PubMedGoogle Scholar
  48. 48.
    Miles DW, Harris WH, Gillett CE, et al. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer. 1999;84:354–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node positive breast cancer according to H ER2 overexpression and other tumor biological variables. J Clin Oncol. 2001;19:329–35.PubMedGoogle Scholar
  50. 50.
    Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92:1991–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topoisomerase as predictive markers in a population of node positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001;12:1081–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Moliterni A, Ménard S, Valagussa P, et al. Her2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer. Proc Am Soc Clin Oncol. 2001;20:23a(Abstract 89).Google Scholar
  53. 53.
    Paik S, Bryant J, Park C, et al. erb B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Nat Cancer Inst. 1998;90:1361–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Thor AD, Berry DA, Budman DR, et al. erb-B2, p-53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Nat Cancer Inst. 1998;90:1346–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study. Clin Cancer Res. 1998;4:7–12.PubMedGoogle Scholar
  56. 56.
    Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103–11.PubMedCrossRefGoogle Scholar
  57. 57.
    Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Jarvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839–47.PubMedCrossRefGoogle Scholar
  59. 59.
    Smith K, Houlbrook 5, Greenall M, et al. Topoisomerase IIa co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 1993;8:933–8.PubMedGoogle Scholar
  60. 60.
    Jarvinen TAH, Kononen J, Pelto-Huikko M, et al. Expression of topoisomerase IIa is associated with rapid cell proliferation, aneuploidy, and c-erb B2 overexpression in breast cancer. Am J Pathol. 1996;148:2073–82.PubMedGoogle Scholar
  61. 61.
    Jarvinen TAH, Tanner M, Barlund M, et al. Characterization of topoisomerase IIa gene amplification and deletion in breast cancer. Genes Chromosomes Cancer. 1999;26:142–50.PubMedCrossRefGoogle Scholar
  62. 62.
    Isola JJ, Tanner M, Holli K, et al. Amplification of topoisomerase IIα is a strong predictor of response to epirubicin based chemotherapy in HER-2/neu positive breast cancer. Breast Cancer Res Treat. 2000;64:31.Google Scholar
  63. 63.
    Nitiss JL, Beck WT. Anti-topoisomerase drug action and resistance. Eur J Cancer. 1996;32A:958–66.PubMedCrossRefGoogle Scholar
  64. 64.
    Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107–16.PubMedGoogle Scholar
  65. 65.
    O’Malley FP, Chia S, Tu D, et al. Prognostic and predictive value of topoisomerase II alpha in randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Proc Am Soc Clin Oncol. 2006;24:11s (Abstract 533).Google Scholar
  66. 66.
    Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 neu positive early breast cancer patients. Breast Cancer Res Treat. 100, 2006, late-breaking abstract 52.Google Scholar
  67. 67.
    Durbecq V, Desmed C, Paesmans M, et al. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 2004;25:1473–9.PubMedGoogle Scholar
  68. 68.
    Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer. 2004;39:288–97.PubMedCrossRefGoogle Scholar
  69. 69.
    Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol. 2005;205:388–96.PubMedCrossRefGoogle Scholar
  70. 70.
    Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004,86:197–206.PubMedCrossRefGoogle Scholar
  71. 71.
    Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96:1141–51.PubMedCrossRefGoogle Scholar
  72. 72.
    Hayes DF, Thor A, Dressler L, et al. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. Proc Am Soc Clin Oncol. 2006;24:5s (Abstract 510).Google Scholar
  73. 73.
    Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP-53 mutation and p-53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6.PubMedGoogle Scholar
  74. 74.
    Di Leo A, Tanner M, Desmedt C, et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol. 2007;Mar 17 [ahead of print].Google Scholar
  75. 75.
    Veitia R, Bissery MC, Martinez C, et al. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumor-bearing mice. Br J Cancer. 1998;78:871–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005;102:8315–20.PubMedCrossRefGoogle Scholar
  77. 77.
    Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–9PubMedCrossRefGoogle Scholar
  78. 78.
    Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24:4236–44.PubMedCrossRefGoogle Scholar
  79. 79.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.PubMedCrossRefGoogle Scholar
  80. 80.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.PubMedCrossRefGoogle Scholar
  81. 81.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRefGoogle Scholar
  82. 82.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–20.PubMedCrossRefGoogle Scholar
  83. 83.
    Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94:S5 (Abstract 1).Google Scholar
  84. 84.
    Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.PubMedCrossRefGoogle Scholar
  85. 85.
    Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8:215.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Laura Biganzoli
    • 1
  1. 1.“Sandro Pitigliani”Medical Oncology Unit, Hospital of Prato, Tuscany Cancer InstituteTuscanyItaly

Personalised recommendations